Literature DB >> 27277967

Short-term therapy with relatively low-dose cerivastatin improves endothelial function independently of its lipid-lowering effect: Evaluation of brachial artery vasodilatation using B-mode ultrasound imaging.

Koichi Sakabe1, Nobuo Fukuda1, Teru Nada1, Yukiko Onose1, Takeshi Soeki1, Hisanori Shinohara1, Yoshiyuki Tamura1.   

Abstract

BACKGROUND AND
OBJECTIVE: Administration of 0.4 to 0.8 mg of cerivastatin per day for 2 weeks has been reported to have pleiotropic effects and improve endothelial function. Whether low-dose cerivastatin would produce these rapid pleiotropic effects in the clinical setting remains uncertain, however. We investigated the effect of short-term therapy with relatively low-dose cerivastatin (0.15 mg/day) on endothelial function, thrombostatic parameters, and C-reactive protein (CRP) levels in hypercholesterolemic patients.
METHODS: Thirteen patients with LDL-cholesterol>160 mg/dl were treated with daily doses of 0.15 mg of cerivastatin for 2 weeks. Endothelial function, thrombostatic parameters (tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-1], and CRP were estimated at baseline and again after 2 weeks of treatment. Endothelial function was measured as flow-mediated vasodilation. Flow-mediated vasodilatation was assessed by measuring the percent change in the diameter of the brachial artery in response to reactive hyperemia using high-resolution ultrasound. Endothelium-independent vasodilatation was also measured using sublingual nitroglycerin.
RESULTS: No major complications developed after the treatment. Total cholesterol decreased significantly, from 258±32 to 211±21 mg/dl, and LDL-cholesterol also decreased from 171±15 to 133±16 mg/dl after the treatment. Flow-mediated vasodilatation increased significantly, from 4.6±1.3 percent to 8.7±3.5 percent after 2 weeks of therapy, although endothelium-independent vasodilatation was not affected (9.5±2.4% vs 8.8±3.1%). No relation was found between percent change in flow-mediated vasodilatation and improvement in levels of LDL-cholesterol after therapy (r=0.07). PAI-1, t-PA, and CRP were not significantly changed by 2 weeks of therapy.
CONCLUSIONS: (1) Evaluating vasodilation of the brachial artery with B-mode ultrasound imaging was useful in investigating the effect of statin on endothelial function. (2) Although no effect was detected in PAI-1, t-PA, or CRP, relatively low-dose cerivastatin therapy for 2 weeks improved endothelial function and lipid level independently and safely in hypercholesterolemic patients.

Entities:  

Keywords:  B-mode ultrasound; brachial artery; cholesterol; endothelial function; statins

Year:  2002        PMID: 27277967     DOI: 10.1007/BF02480853

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  20 in total

1.  Effect of statins on C-reactive protein in patients with coronary artery disease.

Authors:  T E Strandberg; H Vanhanen; M J Tikkanen
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

2.  An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.

Authors:  M Aikawa; E Rabkin; S Sugiyama; S J Voglic; Y Fukumoto; Y Furukawa; M Shiomi; F J Schoen; P Libby
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

3.  Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease.

Authors:  Y Matsuda; H Akita; M Terashima; N Shiga; K Kanazawa; M Yokoyama
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

4.  Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.

Authors:  F González-Fernández; A Jiménez; A López-Blaya; S Velasco; M M Arriero; A Celdrán; L Rico; J Farré; S Casado; A López-Farré
Journal:  Atherosclerosis       Date:  2001-03       Impact factor: 5.162

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

Authors:  L Lacoste; J Y Lam; J Hung; G Letchacovski; C B Solymoss; D Waters
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

7.  Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions.

Authors:  K Egashira; T Inou; Y Hirooka; A Yamada; Y Maruoka; H Kai; M Sugimachi; S Suzuki; A Takeshita
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

8.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Withdrawal of cerivastatin from the world market.

Authors:  Curt D Furberg; Bertram Pitt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.